The incidence of invasive melanoma is rising, and approval for the first immune checkpoint inhibitor (ICI) to treat metastatic melanoma occurred in 2011.
Publications
High Risk Melanoma Patients Can Benefit from Routine Screening and Education
Patients at high risk of melanoma who undergo routine skin cancer screening and education are more likely to be diagnosed with earlier stage melanomas, according to a study published in Cancer Epidemiology, Biomarkers & Prevention
FDA Grants Orphan Drug Designation to Cavrotolimod for Merkel Cell Carcinoma
The FDA has granted an orphan drug designation to cavrotolimod (AST-008) for the treatment of patients with Merkel cell carcinoma (MCC), according to an announcement from Exicure, Inc.1
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin", formerly referred to as ALKS 4230), the company’s investigational engineered interleukin-2 (IL-2) variant immunotherapy, has been granted orphan drug designation for the treatment of mucosal melanoma by the U.S. Food and Drug Administration (FDA).